Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Artiva Biotherapeutics (ARTV) Receivables - Net (2023 - 2024)

Artiva Biotherapeutics (ARTV) has disclosed Receivables - Net for 2 consecutive years, with $569000.0 as the latest value for Q3 2024.

  • For Q3 2024, Receivables - Net changed N/A year-over-year to $569000.0; the TTM value through Sep 2024 reached $569000.0, changed N/A, while the annual FY2023 figure was $1.0 million, N/A changed from the prior year.
  • Receivables - Net hit $569000.0 in Q3 2024 for Artiva Biotherapeutics, roughly flat from $569000.0 in the prior quarter.
  • Across five years, Receivables - Net topped out at $1.0 million in Q4 2023 and bottomed at $569000.0 in Q2 2024.